Evolent Health (EVH) Price to Sales (2015 - 2026)

Evolent Health has reported Price to Sales for 12 years, with the latest figure at 0.94 in Q2 2026.

• On a quarterly basis, Price to Sales fell 68.46% year-over-year to 0.94 in Q2 2026; TTM through Jun 2026 was 0.29, a 51.5% decrease from a year earlier, with the FY2025 full-year figure at 0.24, down 53.64% from the prior year.
• Price to Sales was 0.94 for Q2 2026 at Evolent Health, up from 0.52 in the prior quarter.
• The five-year high for Price to Sales was 10.31 in Q3 2022, with the low at 0.52 in Q1 2026.
• Average Price to Sales over 5 years is 5.14, with a median of 5.63 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Price to Sales rose 21.98% in 2022, then plunged 77.52% in 2026.
• Over 5 years, Price to Sales stood at 8.15 in 2022, then dropped by 15.91% to 6.86 in 2023, then tumbled by 70.41% to 2.03 in 2024, then sank by 53.04% to 0.95 in 2025, then decreased by 1.43% to 0.94 in 2026.
• The last three Price to Sales figures came in at 0.94 (Q2 2026), 0.52 (Q1 2026), and 0.95 (Q4 2025), per Business Quant data.